Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine
- 11 July 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Drug Investigation
- Vol. 36 (10), 783-789
- https://doi.org/10.1007/s40261-016-0433-8
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practiceMultiple Sclerosis and Related Disorders, 2014
- The CARE guidelines: consensus-based clinical case report guideline developmentJournal of Clinical Epidemiology, 2014
- Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current eraEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- PML diagnostic criteriaNeurology, 2013
- Metabolic profile of PML lesions in patients with and without IRISNeurology, 2012
- Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral TherapyPLOS ONE, 2011
- Determinants of survival in progressive multifocal leukoencephalopathyNeurology, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2003
- Tolerability and safety aspects of mirtazapineHuman Psychopharmacology: Clinical and Experimental, 2002